These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1125 related articles for article (PubMed ID: 2129155)

  • 21. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors.
    Waltz DA; Sailor LZ; Chapman HA
    J Clin Invest; 1993 Apr; 91(4):1541-52. PubMed ID: 8386190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model.
    Ma D; Gerard RD; Li XY; Alizadeh H; Niederkorn JY
    Blood; 1997 Oct; 90(7):2738-46. PubMed ID: 9326241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2.
    Laug WE; Cao XR; Yu YB; Shimada H; Kruithof EK
    Cancer Res; 1993 Dec; 53(24):6051-7. PubMed ID: 8261421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
    Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
    Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced production of plasminogen activator activity in human and murine keratinocytes by transforming growth factor-beta 1.
    Keski-Oja J; Koli K
    J Invest Dermatol; 1992 Aug; 99(2):193-200. PubMed ID: 1629632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro.
    Brooks TD; Slomp J; Quax PH; De Bart AC; Spencer MT; Verheijen JH; Charlton PA
    Clin Exp Metastasis; 2000; 18(6):445-53. PubMed ID: 11592301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.
    Soff GA; Sanderowitz J; Gately S; Verrusio E; Weiss I; Brem S; Kwaan HC
    J Clin Invest; 1995 Dec; 96(6):2593-600. PubMed ID: 8675623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model.
    Kobayashi H; Gotoh J; Shinohara H; Moniwa N; Terao T
    Thromb Haemost; 1994 Apr; 71(4):474-80. PubMed ID: 8052966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells.
    Mohanam S; Jasti SL; Kondraganti SR; Chandrasekar N; Kin Y; Fuller GN; Lakka SS; Kyritsis AP; Dinh DH; Olivero WC; Gujrati M; Yung WK; Rao JS
    Clin Cancer Res; 2001 Aug; 7(8):2519-26. PubMed ID: 11489835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of the urokinase receptor in extracellular matrix degradation by HT29 human colon carcinoma cells.
    Reiter LS; Kruithof EK; Cajot JF; Sordat B
    Int J Cancer; 1993 Feb; 53(3):444-50. PubMed ID: 8381394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta.
    Hu ZY; Liu YX; Liu K; Byrne S; Ny T; Feng Q; Ockleford CD
    J Anat; 1999 Feb; 194 ( Pt 2)(Pt 2):183-95. PubMed ID: 10337950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
    Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
    Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
    Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
    van Dam PA; Coelho A; Rolfo C
    Eur J Surg Oncol; 2017 Feb; 43(2):252-257. PubMed ID: 27345498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice.
    Mueller BM; Yu YB; Laug WE
    Proc Natl Acad Sci U S A; 1995 Jan; 92(1):205-9. PubMed ID: 7816818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
    Levenson AS; Kwaan HC; Svoboda KM; Weiss IM; Sakurai S; Jordan VC
    Br J Cancer; 1998 Jul; 78(1):88-95. PubMed ID: 9662256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
    Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
    Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
    Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
    Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.